Journal
VASCULAR PHARMACOLOGY
Volume 82, Issue -, Pages 41-50Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.vph.2016.02.002
Keywords
Cardiovascular disease; Hypertension; Embryonic programming; Epigenetics; Pharmacogenomics; Glucocorticoids
Categories
Funding
- Qatar National Research Fund (a member of Qatar Foundation) [NPRP 4-571-3-171]
Ask authors/readers for more resources
Hypertension is a predominant risk factor for cardiovascular diseases and a major health care burden. Accumulating epidemiological and experimental evidence suggest that adult-onset hypertension may have its origins during early development. Upon exposure to glucocorticoids, the fetus develops hypertension, and the offspring may be programmed to continue the hypertensive trajectory into adulthood. Elevated oxidative stress and deranged nitric oxide system are not only hallmarks of adult hypertension but are also observed earlier in life. Endothelial dysfunction and remodeling of the vasculature, which are robustly associated with increased incidence of hypertension, are likely to have been pre-programmed during fetal life. Apparently, genomic, non-genomic, and epigenomic factors play a significant role in the development of hypertension, including glucocorticoid-driven effects on blood pressure. In this review, we discuss the involvement of the aforementioned participants in the pathophysiology of hypertension and suggest therapeutic opportunities for targeting epigenome modifiers, potentially for personalized medicine. (C) 2015 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available